台股 » 個股 » 中化生 » 籌碼相關 » 券商分點績效

中化生

(1762)
可現股當沖
  • 股價
    46.85
  • 漲跌
    ▼0.90
  • 漲幅
    -1.88%
  • 成交量
    171
  • 產業
    上市 生技醫療類股
  • 251人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
中化生 (1762)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/04/20 ~ 2024/04/27     後一日»

券商獲利排行 - 2024/04/20 ~ 2024/04/27

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  3.54%111.6-1.1112.762708454544.946.9
  3.59%109.9-2.3112.3636854545.144.646.9
  3.70%1032.9100.150621244.944.845.146.9
  2.73%83.30.183.342682644.944.944.946.9
  3.26%26.5-0.627.11718145.245.344.746.9
  4.21%20.8020.8111104545046.9
  4.34%19.5019.51010044.944.9046.9
  4.11%18.5018.5101004545046.9
  2.36%17.2-0.918.11316345.445.545.246.9
  3.53%160161010045.345.3046.9
  1.06%15.72.912.87332645.14545.146.9
  4.26%15.3015.388044.944.9046.9
  3.21%132.710.35944544.845.546.9
  3.46%12.5012.578045.345.345.346.9
  0.83%11.22.58.74302545.145.145.246.9
  3.96%10.7010.766045.145.1046.9
  4.34%9.709.755044.944.9046.9
  4.11%9.209.25504545046.9
  4.11%9.209.25504545046.9
  3.42%7.707.755045.345.3046.9
  4.30%7.707.744044.944.9046.9
  3.35%7.607.655045.345.3046.9
  3.31%7.507.555045.445.4046.9
  4.13%7.407.44404545046.9
  3.19%7.207.255045.445.4046.9
  3.65%6.606.644045.245.2046.9
  4.89%6.506.533044.744.7046.9
  4.58%6.106.133044.844.8046.9
  3.30%5.90.35.7341454545.346.9
  4.34%5.805.833044.944.9046.9
  3.19%5.80.55.334145.245.145.646.9
  4.11%5.505.53304545046.9
  2.42%5.4-0.15.6352454544.946.9
  5.28%4.704.722044.544.5046.9
  4.93%4.404.422044.744.7046.9
  3.19%4.304.333045.445.4046.9
  4.81%4.304.322044.744.7046.9
  4.16%3.703.72204545046.9
  4.11%3.703.72204545046.9
  4.00%3.603.622045.145.1046.9
  4.00%3.603.622045.145.1046.9
  4.00%3.603.622045.145.1046.9
  3.88%3.503.522045.145.1046.9
  3.88%3.503.522045.145.1046.9
  3.77%3.403.422045.245.2046.9
  3.65%3.303.322045.245.2046.9
  3.42%3.103.122045.345.3046.9
  3.42%3.103.122045.345.3046.9
  3.42%3.103.122045.345.3046.9
  6.96%30311043.843.8046.9

券商虧損排行 - 2024/04/20 ~ 2024/04/27

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -5.22%-76.60-76.6-3203344.54544.546.9
  -3.55%-75.3-0.2-75.1-4254745.145.145.146.9
  -1.66%-70.97.5-78.5-4352954544.94546.9
  -3.49%-69.40-69.4-4404445.3045.346.9
  -3.51%-41.11.3-42.4-242264544.545.146.9
  -3.75%-22-0.3-21.7-1111345.145.34546.9
  -4.81%-21.50-21.5-901044.745.344.746.9
  -4.30%-21.20-21.2-1101144.9044.946.9
  -4.08%-20.20-20.2-100114545.24546.9
  -5.16%-18.40-18.4-80844.6044.646.9
  -3.73%-16.80.3-17.1-811044.944.64546.9
  -4.00%-16.20-16.2-90945.1045.146.9
  -3.65%-13.20-13.2-80845.2045.246.9
  -4.05%-12.70-12.7-7074504546.9
  -6.96%-12.20-12.2-40443.8043.846.9
  -4.42%-11.90-11.9-60644.9044.946.9
  -5.28%-11.70-11.7-50544.5044.546.9
  -4.27%-11.50-11.5-60644.9044.946.9
  -4.05%-10.90-10.9-6064504546.9
  -4.61%-10.30-10.3-50544.844.144.846.9
  -4.58%-10.20-10.2-50544.8044.846.9
  -3.45%-9.30.1-9.4-51644.944.84546.9
  -3.88%-8.70-8.7-50545.1045.146.9
  -3.88%-8.70-8.7-50545.1045.146.9
  -2.32%-8.40.2-8.6-43845.145.145.146.9
  -4.46%-80-8-30444.945.244.946.9
  -3.42%-7.70-7.7-40545.345.545.346.9
  -4.26%-7.60-7.6-40444.9044.946.9
  -4.23%-7.60-7.6-4044504546.9
  -4.00%-7.20-7.2-40445.1045.146.9
  -4.00%-7.20-7.2-40445.1045.146.9
  -3.84%-6.90-6.9-40445.145.445.146.9
  -5.04%-6.70-6.7-20344.645.144.646.9
  -5.01%-6.70-6.7-30344.6044.646.9
  -3.48%-6.30-6.3-40445.3045.346.9
  -4.61%-6.20-6.2-20344.845.644.846.9
  -3.34%-6.10-6.1-40445.345.145.346.9
  -4.23%-5.70-5.7-2034545.34546.9
  -1.04%-5.6-0.8-4.8-391245.345.345.246.9
  -4.11%-5.50-5.5-3034504546.9
  -4.11%-5.50-5.5-3034504546.9
  -3.88%-5.20-5.2-20345.144.845.146.9
  -2.61%-4.70.5-5.2-3144544.645.146.9
  -5.16%-4.60-4.6-10244.645.144.646.9
  -5.04%-4.50-4.5-20244.6044.646.9
  -5.05%-4.50-4.5-10244.644.144.646.9
  -1.66%-4.50.3-4.8-33645.245.245.346.9
  -3.33%-4.5-0.6-3.9-21345.145.544.946.9
  -4.93%-4.40-4.4-10244.745.344.746.9
  -4.81%-4.30-4.3-20244.7044.746.9
中化生魚油原料藥產能倍增最快年底過美認證 明年營收再登高Anue鉅亨-2022/11/14
年度傑出生技產業獎 中化生、藥華藥入列Anue鉅亨-2022/07/22
〈中國限電〉中印限電危機原料藥再度供給失衡 中化生、台耀迎轉單潮Anue鉅亨-2021/10/07
中化生 相關文章